BIOBRIEF
An Essex led team shares an open library of redesigned 'intrabodies': small antibody fragments built to stay stable inside human cells, where most neurodegenerative damage starts.
A team at the University of Essex has turned 672 antibodies into something rarer: intrabodies, or antibody fragments engineered to stay stable and function inside human cells. The work, published in Nature Communications and funded by the MND Association, rests on an insight. Electrical charge is what keeps most antibody fragments from surviving inside a cell without clumping together. AI protein-design software from David Baker's lab — described by lead author Dr. Caitlin O'Shea as a Nobel Prize winner — let the team rebuild 672 fragments with the right charge and stability to function where disease targets actually live.
The targets named in the paper are Alzheimer's, Parkinson's, Huntington's and motor neurone disease (MND), all of which involve proteins that misbehave from inside neurons, beyond the reach of cell-surface antibody drugs. Dr. Caitlin O'Shea specializes in MND and Parkinson's. "We looked at the properties of millions of antibodies and compared them with human proteins found inside the cell. From this we figured out that antibodies usually have the wrong charge to exist inside cells without sticking together," said lead author Dr. Caitlin O'Shea.
The work is preclinical. No patient data is in the paper, and the charge-redesign result is a property insight, not a clinical one. The 672 designs will be made freely available after publication, giving labs a shared toolkit to test and build on.
The press release frames this as unlocking new treatments. The paper is more modest and, in the long run, more useful: a new way to design antibodies that work where the disease happens.